Moderate riskFDA DrugClass II

Major Pharmaceuticals levothyroxine tablets recalled for subpotency

Major Pharmaceuticals is recalling one lot of levothyroxine sodium 150 mcg tablets because they do not contain the full stated dose of active ingredient. Patients taking this medication need the correct dose to manage their thyroid condition properly.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have levothyroxine tablets from Major Pharmaceuticals with lot #N02167 and expiration date 07/2026 (NDC 0904-6956-61)
  2. Contact your pharmacy or doctor if you have this lot
  3. Do not stop taking your levothyroxine without talking to your doctor first

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6956-61
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 12 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Classification
Class II
Recall number
D-0706-2026

In the FDA's words

Description
Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6956-61 Subpotent Drug Lot #: N02167, Exp. Date 07/2026 Distribution: Nationwide in the USA. Affected quantity: N/A
Hazard
Subpotent Drug

12 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

PotencyDrugsSold nationwideMore from FDA Drug